A minimal comprehensive somatic panel to aid clinical decision making in a low cost setting. Landscape of genomic alterations in genes implicated in the regulation of hypoxia inducible factor (HIF) ...

AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...

Natera (NTRA) is back in focus after publishing new peer reviewed data on its Signatera cancer assay and rolling out the Zenith genomics rare disease platform. These developments sharpen attention on ...

The formal launch of the BGI/Natera Signatera Assay is the next step towards achieving global access to personalized ctDNA testing AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ -- ...

Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now ...

Natera Inc. (NASDAQ:NTRA) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Leerink Partners analysts reiterated their Outperform rating on Natera Inc.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the ...

Thanks to improvements in early detection and personalized treatment, people with breast cancer experience better outcomes than ever before. 1 However, identifying and monitoring patients at high risk ...

AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...